Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

• Status: Completed
• Trial end date: 2016-04-18

Summary

This study is aimed to evaluate the efficacy and safety between Tedizolid 200mg daily (intra venous) I.V. to oral for 6-day treatment compared with that of Linezolid 600mg twice daily I.V. to oral for 10-day treatment Acute Bacterial Skin and skin structure infection (ABSSSI).This is a double-blind, randomized, active control, 7-10days treatment for all subjects.

• Phase: Phase 3

Details

• Lead Sponsor: Bayer
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Linezolid; Oxazolidinones; Tedizolid; Torezolid; Torezolid phosphate